BioSpace News Archive

Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day , December 14, from 10:00 a.m. - 12:30 p.m. ET.

Foundation Medicine, Inc., announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer.

Anixa Biosciences, Inc. today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P. Morgan Healthcare Conference (“JPM Week 2024").

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD).

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Larkspur Biosciences announced that its Chief Executive Officer, Catherine Sabatos-Peyton, PhD, will participate in the following upcoming biotech events, including two events surrounding the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco:.

Nicox SA, an international ophthalmology company, announced that new nonclinical data on NCX 470 demonstrating greater intraocular pressure lowering than Lumigan® upon both single and repeated dosing in an in vivo nonclinical model has been published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, emerged from stealth with the announcement of its successful Series A fundraise.

1ST Biotherapeutics, Inc. announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.

The Japan-based Global Health Innovative Technology Fund announced that it will invest approximately US$3.3 million in a global multicenter Phase III clinical trial project led by Fosun Pharma for a triple artemisinin combination drug against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.